I've been tracking some interesting moves in the small cap medical device companies space lately, and honestly, the sector's been pretty compelling this year. The whole medical device industry is projected to hit 1.3 trillion by 2029 from around 810 billion in 2024 - that's nearly 10% annual growth. With chronic diseases pushing demand and AI plus wearables reshaping how devices work, there's real opportunity here.

Let me break down five small cap medical device companies that caught my attention. These are NASDAQ-listed names with market caps between 50 million and 500 million, and they've all had solid runs.

Delcath Systems (DCTH) is probably the most dramatic story. Up over 200% year-over-year. They're focused on liver cancer treatment using their Hepzato Kit - basically combining a delivery system with chemotherapy. The stock really moved in Q2 2024 after some encouraging trial results showed up, then again in late August when German research validated their approach. December brought FDA clearance for a Phase 2 trial on colorectal cancer, which sent it higher. By January they were posting 37 million in full-year revenue. Pretty wild trajectory for a small cap medical device play.

Sensus Healthcare (SRTS) is another one that's been moving. Up around 148%. They do superficial radiotherapy for skin cancer and keloids. The story here was solid Q1 results - revenue jumped from 3.4 million to 10.7 million year-over-year. They also scored their first Asia sale of their SRT-100 Vision system and even expanded into veterinary use in Israel. By November their Q3 numbers showed continued momentum with 8.8 million in revenue.

Pro-Dex (PDEX) manufactures surgical instruments for orthopedic and dental markets. Up 118% or so. What's interesting is the stock was quiet for most of 2024 but really accelerated in the final months. September brought strong fiscal year results - 53.8 million in net sales, up 17% year-over-year. Then October's Q1 2025 numbers showed 25% growth. That's the kind of small cap medical device momentum that gets attention.

AngioDynamics (ANGO) is a broader play in minimally invasive devices across vascular access, surgery, and oncology. Up 92%. They got FDA clearance for their AlphaVac thrombectomy device in July, which opened up new markets. Then in December they got clearance for NanoKnife for prostate ablation. By January their Q2 2025 revenue hit 73 million, up 9% year-over-year.

Last one is KORU Medical Systems (KRMD), up about 86%. They make infusion systems and syringe drivers. Most of their gains came in the final months of 2024 after presenting data at a drug delivery conference showing nurses prefer their FreedomEdge system. Q3 revenue came in at 8.2 million, up 17%.

The pattern I'm seeing across these small cap medical device companies is that positive clinical data and revenue growth actually moves the needle. These aren't speculative plays - they're companies with real products, real revenue, and real clinical validation. The sector tailwinds around aging populations and chronic disease management are real too. Definitely worth keeping on your radar if you're looking at this space.